Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease

Medicine and Dentistry

• Tumor Necrosis Factor 100%
• Adverse Event 100%
• Inflammatory Bowel Disease 100%
• Virus Infection 33%
• Biological Therapy 33%
• Adalimumab 33%
• Infliximab 33%
• Golimumab 33%
• Disease 16%
• Immune System 16%
• Bacterial Infection 16%
• Adverse Effect 16%
• Autoimmunity 16%
• Infusion 16%
• Ulcerative Colitis 16%
• Cancer 16%
• Crohn's Disease 16%
• Bloodstream Infection 16%
• Monoclonal Antibody 16%
• Biosimilar 16%
• Mycosis 16%
• Sulfhemoglobinemia 16%
• Opportunistic Infection 16%
• Side Effect 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Adverse Event 100%
• Inflammatory Bowel Disease 100%
• Virus Infection 33%
• Adalimumab 33%
• Infliximab 33%
• Golimumab 33%
• Monoclonal Antibody 16%
• Ulcerative Colitis 16%
• Crohn's Disease 16%
• Bacterial Infection 16%
• Hematologic Disease 16%
• Opportunistic Infection 16%
• Biosimilar Agent 16%
• Bloodstream Infection 16%
• Mycosis 16%
• Side Effect 16%